{
    "id": 29556,
    "fullName": "MET - UBE2H",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MET-UBE2H results from the fusion of MET and UBE2H (PMID: 30244854). MET-UBE2H has been identified in lung adenocarcinoma (PMID: 30244854), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 14471,
                    "pubMedId": 30244854,
                    "title": "MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30244854"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4233,
        "geneSymbol": "MET",
        "terms": [
            "MET",
            "AUTS9",
            "c-Met",
            "DFNB97",
            "HGFR",
            "RCCP2"
        ]
    },
    "variant": "MET - UBE2H",
    "createDate": "03/14/2019",
    "updateDate": "10/24/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 7328,
                "geneSymbol": "UBE2H",
                "terms": [
                    "UBE2H",
                    "E2-20K",
                    "GID3",
                    "UBC8",
                    "UBCH",
                    "UBCH2"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 16374,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR E746_S752delinsV developed progressive disease after remained on Tarceva (erlotinib) treatment for 33 months, a MET-UBE2H fusion was identified by liquid biopsy at the time of pregression (PMID: 30244854).",
            "molecularProfile": {
                "id": 31615,
                "profileName": "MET - UBE2H EGFR E746_S752delinsV"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14471,
                    "pubMedId": 30244854,
                    "title": "MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30244854"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16375,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in partial response and progression-free survival for more than 6.5 months in a patient with lung adenocarcinoma harboring EGFR E746_S752delinsV and MET-UBE2H fusion (PMID: 30244854).",
            "molecularProfile": {
                "id": 31615,
                "profileName": "MET - UBE2H EGFR E746_S752delinsV"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14471,
                    "pubMedId": 30244854,
                    "title": "MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30244854"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31614,
            "profileName": "MET - UBE2H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31615,
            "profileName": "MET - UBE2H EGFR E746_S752delinsV",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}